Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Abstract

The serine/threonine kinase Polo-like kinase 1 (Plk1) is overexpressed in many types of human cancers, and has been implicated as an adverse prognostic marker for cancer patients. Plk1 localizes to its intracellular anchoring sites via its polo-box domain (PBD). Here we show that Plk1 can be inhibited by small molecules which interfere with its intracellular localization by inhibiting the function of the PBD. We report the natural product thymoquinone and, especially, the synthetic thymoquinone derivative Poloxin as inhibitors of the Plk1 PBD. Both compounds inhibit the function of the Plk1 PBD in vitro, and cause Plk1 mislocalization, chromosome congression defects, mitotic arrest, and apoptosis in HeLa cells. Our data validate the Plk1 PBD as an anticancer target and provide a rationale for developing thymoquinone derivatives as anticancer drugs.

DOI: 10.1016/j.chembiol.2008.03.013
01002003002008200920102011201220132014201520162017
Citations per Year

1,345 Citations

Semantic Scholar estimates that this publication has 1,345 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Reindl2008InhibitionOP, title={Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.}, author={Wolfgang Reindl and Juping Yuan and Andrea Kr{\"a}mer and Klaus I Strebhardt and Thorsten Berg}, journal={Chemistry & biology}, year={2008}, volume={15 5}, pages={459-66} }